The paper highlights the personality of the founder of European student exchange program ERASMUS (EuRopean Community Action Scheme for the Mobility of University Students) Erasmus of Rotterdam. He was one of the leading European humanists and has left a literary legacy of large dimensions. His thoughts, ideas, opinions, and mainly the works have a great benefit for society even today. From 16th century to the present time they are the subject of unchanged interest.

Download full-text PDF

Source

Publication Analysis

Top Keywords

erasmus rotterdam
8
ideas persist
4
persist centuries
4
centuries erasmus
4
rotterdam prince
4
prince humanists
4
humanists paper
4
paper highlights
4
highlights personality
4
personality founder
4

Similar Publications

Highly sensitized (HS) patients in need of kidney transplantation (KTx) typically spend a longer time waiting for compatible kidneys, are unlikely to receive an organ offer, and are at increased risk of antibody-mediated rejection (AMR). Desensitization using imlifidase, which is more rapid and removes total body immunoglobulin G (IgG) to a greater extent than other methods, enables transplantation to occur between HLA-incompatible (HLAi) donor-recipient pairs and allows patients to have greater access to KTx. However, when the project was launched there was limited data and clinical experience with desensitization in general and with imlifidase specifically.

View Article and Find Full Text PDF

Background: A considerable proportion (21%) of patients with common variable immunodeficiency (CVID) suffers from depression. These subjects are characterized by reduced naïve T cells and a premature T cell senescence similar to that of patients with major depressive disorder (MDD). It is known that T cells are essential for limbic system development/function.

View Article and Find Full Text PDF

Introduction: Ecological momentary assessment (EMA) is popular in smoking research to study time-varying processes and design just-in-time personalised cessation interventions. Yet, research examining the psychometric properties of EMA and user experiences with EMA protocols is lacking. We conducted a mixed-methods study to test the EMA component of a mobile intervention for middle to late-aged adolescents (16-20 years) who smoke cigarettes at least weekly.

View Article and Find Full Text PDF

Introduction: Benralizumab is an interleukin 5-receptor-blocking drug registered for the treatment of eosinophilic asthma. It has proven efficient and safe in a small phase-II trial in hypereosinophilic syndrome and is currently being investigated in a larger, randomized phase-III trial. We report on real-world experience with benralizumab in 15 patients with severe Hypereosinophilic syndrome (HES) that were refractory to other treatments or on unacceptable steroid doses.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!